web analytics

A Non-Hormonal Therapeutic Platform For Targeting M6A Regulators To Treat Uterine Fibroids

Published:
Lead Inventor: Qiwei Yang
Print or Save to PDF

SUMMARY

A non-hormonal therapeutic strategy for uterine fibroids targeting the upregulated m6A regulator METTL3 employing small molecule inhibitors thereby reducing fibroid cell proliferation and increasing apoptosis.

 

The Unmet Need: Novel therapies that target fibroid growth without relying on hormonal manipulation

  • Uterine fibroids are the most common benign tumors affecting the female reproductive system, with up to 80% of women developing them at some point in their lives. These growths, originating from the smooth muscle layer of the uterus, can lead to a range of debilitating symptoms including heavy menstrual bleeding, anemia, pelvic pain, infertility, and complications during pregnancy. The significant impact of fibroids on quality of life, combined with their high prevalence, underscores the urgent need for effective and accessible treatments. Despite their hormone-dependent nature, current management options are often limited to surgical interventions such as hysterectomy or myomectomy, or to hormone-based therapies that can have undesirable side effects and are not suitable for all patients, particularly those wishing to preserve fertility.

  • Existing approaches to treating uterine fibroids are fraught with limitations. Surgical procedures, while effective, carry risks such as infection, bleeding, and long recovery periods, and are not always feasible for women desiring future preExisting approaches to treating uterine fibroids are fraught with limitations. Surgical procedures, while effective, carry risks such as infection, bleeding, and long recovery periods, and are not always feasible for women desiring future pregnancies. Hormonal therapies, including gonadotropin-releasing hormone (GnRH) agonists and antagonists, can induce menopausal symptoms, bone loss, and are generally not recommended for long-term use. Moreover, these treatments often fail to provide lasting relief, as fibroids frequently recur once therapy is discontinued. Non-hormonal and non-invasive alternatives are virtually nonexistent, leaving a significant gap in care for women who cannot tolerate hormones or wish to avoid surgery.

The Proposed Solution: Small molecule inhibitors to target and reduce METTL3, a protein in upregulated in uterine fibroids, offering a promising non-hormonal and non-invasive treatment option for fibroids

  • The faculty inventor developed a novel, non-hormonal therapeutic approach for treating uterine fibroids by targeting the m6A RNA modification pathway, specifically focusing on the m6A "writer" enzyme METTL3. Research has demonstrated that METTL3 and other m6A regulators are consistently upregulated in fibroid cells compared to normal myometrial cells. Experimental studies using both human and animal tissues, as well as in vitro assays, have shown that reducing METTL3 levels leads to decreased cell proliferation and increased programmed cell death in fibroid cells, suggesting a promising therapeutic effect. The proposed solution utilizes small molecule inhibitors to selectively inhibit METTL3 activity in fibroid tissues.

  • What differentiates this technology is its targeted, non-hormonal mechanism of action, which addresses a critical unmet need for safer, long-term fibroid management options. By focusing on METTL3 and related m6A regulators, the therapy offers high specificity, potentially minimizing off-target effects and preserving normal tissue function. The use of small molecule inhibitors further enhances the practicality of the treatment, allowing for non-invasive administration and easier integration into clinical practice. This innovative strategy represents a significant advancement over existing therapies by providing a targeted, effective, and less invasive option for women suffering from uterine fibroids.

ADVANTAGES

ADVANTAGES

  • Provides a non-hormonal therapeutic option for uterine fibroids, avoiding hormone-related side effects

  • Targets the m6A RNA modification pathway, a novel and specific mechanism involved in fibroid pathogenesis

  • Potentially offers a non-invasive treatment alternative to surgery or hysterectomy

  • May improve fertility and reduce fibroid-associated symptoms such as menometrorrhagia and pelvic pressure

APPLICATIONS

  • Non-hormonal uterine fibroid treatment

  • Drug development for gynecological disorders

  • Personalized medicine for fibroid patients

  • Demonstrated efficacy in both human and animal fibroid models, supporting translational relevance